Influencing the decline of lung function in COPD: use of pharmacotherapy.

The annual rate of decline in FEV 1 was 50 mL/year in the fluticasone group and 59 mL/year in the placebo group, although the difference did not reach statistical significance ( P = 0.16). 63 A third contemporary trial by Pauwels and colleagues randomized over 1200 patients to budesonide or placebo for 3 years, and again, the rate of decline was not statistically significantly different ( P = 0.39) between budesonide (−57 mL/year) vs placebo (−69 mL/year).

also in 111,027 other papers